Lifecore Biomedical (LFCR) | Stock Overview & Key Data
Lifecore Biomedical Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $20.75 on May 20, 1996
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Lifecore Biomedical
LFCR
|
184.39M Micro-cap | -1.44% | 24.77% | 25.63% | -30.33% | -29.07% | -16.20% | -31.88% | -50.83% | -48.63% | -4.73% | -36.20% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
Aurora Cannabis
ACB
|
200.44M Micro-cap | -2.95% | -8.04% | -28.14% | -36.47% | -39.40% | -48.03% | -43.70% | -96.52% | -93.07% | -95.89% | -95.89% |
|
Anika Therapeutics
ANIK
|
221.65M Micro-cap | 0.07% | -2.01% | 1.74% | 52.66% | 56.26% | 34.68% | -44.60% | -63.19% | -70.02% | 116.79% | 39.13% |
| 203.22M Micro-cap | -3.74% | -3.74% | -27.46% | -42.78% | -40.46% | -24.29% | -39.77% | -90.89% | -96.46% | -96.46% | -96.46% |
Ownership & Short Interest
Calculate Your Lifecore Biomedical Investment Returns
Long-Term Investment Performance Analysis
Lifecore Biomedical stock price in Jul 2016 was $11.41, A $1,000.00 lump sum investment in Lifecore Biomedical made 9 years ago would be worth approximately $481.16 today, representing a negative return of -51.88%. This translates to an annualized return (CAGR) of -7.12%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is LFCR's 52-week high and low?
- In the last 52 weeks, Lifecore Biomedical reached a high of $8.98 (on January 27, 2026) and a low of $3.63 (on March 31, 2026).
- What is the market cap and P/E ratio for LFCR?
- Curious about Lifecore Biomedical's size and valuation? Its market capitalization stands at 184.39M. When it comes to valuation, the P/E ratio (trailing twelve months) is 56.23, and the forward P/E (looking ahead) is -6.30.
- Does LFCR pay dividends? If so, what's the yield?
- As for dividends, Lifecore Biomedical isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Lifecore Biomedical's main competitors or similar companies to consider before investing?
When looking at Lifecore Biomedical, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% Aurora Cannabis
ACB200.44M Healthcare Drug Manufacturers - Specialty & Generic -48.03% -43.70% Anika Therapeutics
ANIK221.65M Healthcare Drug Manufacturers - Specialty & Generic 34.68% -44.60% Organigram Holdings
OGI203.22M Healthcare Drug Manufacturers - Specialty & Generic -24.29% -39.77% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Lifecore Biomedical Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Lifecore Biomedical's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 312.34%, the Debt to Equity ratio from the most recent quarter is 414.80, and its Gross Profit Margin stands at 25.04%.
- What is the recent revenue and earnings growth for LFCR?
- Looking at Lifecore Biomedical's growth, its revenue over the trailing twelve months (TTM) was $129M. Compared to the same quarter last year (YoY), quarterly revenue grew by -14.64%, and quarterly earnings saw a YoY growth of 25.92%.
- How much of LFCR stock is held by insiders and institutions?
- Wondering who owns Lifecore Biomedical stock? Company insiders (like executives and directors) hold about 1.92% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 76.45%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.